Realizing the untapped potential of liquid biopsy

Optimizing patient care requires non-invasive tests for disease diagnosis, monitoring, and prognosis.

Other diagnosis techniques, such as genomic based liquid biopsies, are unsuitable for most conditions outside of oncology, and incur high costs for population-wide screening.

MetaSight develops and deploys accurate, affordable, and accessible diagnostics for diverse diseases through a single blood test – applicable for population scale screening.

Our approach leverages the world’s largest clinico multi-OMICS database, generated using our proprietary unbiased metabolomics, lipidomics, and proteomics platform.